Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Transferase other than ribonuclease
Reexamination Certificate
2001-09-13
2003-07-15
Prouty, Rebecca E. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Transferase other than ribonuclease
C435S015000
Reexamination Certificate
active
06593121
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to human diacylglycerol kinase proteins (hDAGK) and particularly to human diacylglycerol kinase &bgr; (hDAGK&bgr;) protein, and to related nucleotide sequences, expression vectors, cell lines, antibodies, screening methods, compounds, methods of production and methods of treatment, as well as other related aspects.
BACKGROUND OF THE INVENTION
Diacylglycerol kinases (DAGKs) are a family of enzymes that convert diacylglycerol (DAG) to phosphatidic acid and are therefore known to attenuate DAG-dependent protein kinase C activation (PCK) (1).
Five types of DAGKs have been described. Type I DAGKs contains four conserved regions, the N-terminal region (C 1), two sets of EF-hand motifs (C2), two cysteine-rich zinc finger like structures (C3) and the C-terminal region (C4). Type II isoenzymes contain a pleckstrin homology (PH) domain at the N-terminus. Type Ill contains only the zinc finger (C3) and the catalytic region (C4). Type IV contains four ankyrin repeats near the carboxyl terminus. Type V contains three instead of two zinc finger structures, a proline-rich region and a PH domain with an overlapping Ras-associating (RA) domain. All share two domains, the C2 and the C3 (2).
A 90 kDa DAGK&bgr; (3) belonging to type I was found by screening a rat brain cDNA library using fragments of rat a DAGK cDNA under low stringency conditions. The cDNA clone obtained was completely sequenced. The rat DAGK&bgr; cDNA has an open reading frame of 5927 nucleotides and encodes for a protein of 801 amino acids with a predicted relative molecular mass of 90,000. Analysis of the amino acid sequence identified 2 EF-hand motifs (aa 152-180 and 197-225), of two cysteine-rich zinc-finger-like sequences (aa 257-292 and 319-356), and putative ATP-binding sites (aa 266-294 and 533-560).
Brain expression has been described for the known DAGK isoforms (2), which include DAGK&agr;, DAGK&eegr;, DAGK&zgr; and DAGK&thgr;. A particular distribution restricted to specific regions of the central nervous system (CNS) was described for the DAGK&bgr; form, originally identified in the rat (90 Da DAGK&bgr;). The rat beta form is predominantly localised in neurons of the caudate-putamen, the accubens nucleus and the olfactory tubercle. Such brain regions are among the main CNS dopaminergic, serotonergic, acetylcholinergic and glutamatergic terminal fields (4).
It has also been demonstrated that some metabotropic dopamine, serotonin, glutamate, acetylcholine and several peptide receptors are coupled with the phosphoinositide signal transduction system (5). Lithium is known as one of the most effective therapies for bipolar disorders. Although the biological mechanisms of the mood stabilising properties of lithium are not well understood, experimental evidence indicates that lithium modulates the phosphoinositide signal transduction system (6) by inhibiting the phosphatase that liberates inositol from inositol phosphate (IP), and by modifying the activity of the phospholipase C (PLC)-dependent signalling pathways, including the levels of the second messenger diacylglycerol (DAG) that activates protein kinase C (PKC).
With this background in mind, the present inventors have determined that the DAGKs, and particularly the human ortholog of rat 90 kDa DAGK&bgr; (hDAGK&bgr;) and variants thereof will provide targets for the development of novel mood stabilising agents and therapeutic agents for treatment of other disorders.
Clearly there is a need for proteins and related nucleotide sequences that may be used to screen for mood stabilising agents and which may also play a role in preventing, ameliorating or correcting mood disorders and dysfunction and other neurological diseases.
Accordingly, it is an object of the present invention to identify targets for screening of novel therapeutic agents. It is another object of the invention to locate and characterise human DAGK&bgr; and variants thereof. Other objects of the present invention will become apparent from the following detailed description thereof.
SUMMARY OF THE INVENTION
According to one embodiment of the present invention there is provided an isolated human diacylglycerol kinase &bgr; (hDAGK&bgr;) protein or a variant thereof. In a particularly preferred embodiment of this invention the human diacylglycerol kinase &bgr; (hDAGK&bgr;) has the amino acid sequence set out in Seq ID No 1 or Seq ID No 4. The hDAGK&bgr; protein having the amino acid sequence set out in Seq ID No 4 is referred to as SV-hDAGK&bgr; protein.
According to one embodiment of the present invention there is provided a nucleotide sequence encoding a human diacylglycerol kinase &bgr; (hDAGK&bgr;) protein or a variant thereof, or a nucleotide sequence that is complementary thereto. In a particular preferred embodiment of the invention the polynucleotide comprises the sequence set out in Seq ID No 3 or Seq ID No 6. The hDAGK&bgr; protein having the polinucletide sequence set out in Seq ID No 6 is referred to as SV-hDAGK&bgr; protein.
In accordance with another aspect of the invention there is provided an expression vector comprising a nucleic acid sequence as referred to above which is capable of expressing a hDAGK&bgr; protein.
According to a further aspect of the invention there is provided a stable cell line comprising an expression vector as referred to above. Preferably the cell line is a modified HEK293T, CHO, HeLa, Sf9 or COS cell line.
According to yet a further aspect of the invention there is provided an antibody specific for a hDAGK&bgr; protein.
According to still another aspect of the invention there is provided a method for identification of a compound that exhibits DAGK modulating activity, comprising contacting a DAGK protein with a test compound and detecting modulation of enzyme activity or detecting enzyme inactivity. Preferably the DAGK is hDAGK&bgr; or a variant thereof.
According to another aspect of the invention there is provided a compound which modulates hDAGK activity, identifiable by the method referred to above. Preferred compounds according to the present invention are those that modulate hDAGK&bgr; activity or a variant thereof.
According to another aspect of the invention there is provided a compound that modulates hDAGK activity. Preferred compounds according to the present invention are those that modulate hDAGK&bgr; activity or a variant thereof.
According to a further aspect of the invention there is provided a method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient, which comprises administering to said patient an effective amount of a compound as referred to above. Conveniently the hDAGK is hDAGK&bgr; or a variant thereof. Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease.
According to a further aspect of the invention there is provided a method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient which comprises administering to said patient an effective amount of a modulator of hDAGK activity. Conveniently the hDAGK is hDAGK&bgr; or a variant thereof. Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease.
According to another aspect of the invention there is provided use of a compound as referred to above in a method of formulating a medicament for treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient. Conveniently the hDAGK is hDAGK&bgr; or a variant thereof. Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease.
According to another aspect of the invention there is provided use of a modulator of hDAGK activity i
Caldara Fabrizio
Caricasole Andrea
Sala Cinzia Felicita
Bennett Virginia C.
Prouty Rebecca E.
SmithKline Beecham Corporation
Swope Sheridan L.
LandOfFree
Human diacylglycerol kinase &bgr; (HDAGK&bgr;) protein and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human diacylglycerol kinase &bgr; (HDAGK&bgr;) protein and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human diacylglycerol kinase &bgr; (HDAGK&bgr;) protein and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3045800